Literature DB >> 9679224

A parametric confidence interval for a moment-based scaled criterion for individual bioequivalence.

E K Kimanani1, D Potvin.   

Abstract

Confidence intervals of proposed individual bioequivalence metrics are difficult to determine in closed form because their stochastic distributions are unknown. In this article, it is shown that, with slightly modified weights, the Relative Individual Risks (RIR) moment-based scaled statistic for individual bioequivalence that was presented by Schall and Williams has an exact noncentral Fisher's F distribution with noncentrality parameter give by a scaled squared difference in formulations means. This can be approximated by a central F with adjusted degrees of freedom from which it follows that an upper (1-alpha) confidence bound for RIR is given by [formula: see text] where [formula: see text] is the least square estimate of RIR; dfER is the degrees of freedom associated with the reference intrasubject variance estimate, v is the subject-by-formulation degrees of freedom adjusted for noncentrality and alpha is the significance level. Individual bioequivalence is concluded if UL does not exceed the regulatory limit. The performance of this confidence interval was investigated by comparing its experimental bioequivalence rate to that of the unweighted metric under known parameter situations through simulations of two formulations in a fully replicated study design. Results showed that the proposed metric is slightly less biased and more precise than the unweighted metric.

Mesh:

Year:  1997        PMID: 9679224     DOI: 10.1023/a:1025717414526

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  5 in total

1.  Bioequivalence revisited.

Authors:  L B Sheiner
Journal:  Stat Med       Date:  1992-09-30       Impact factor: 2.373

2.  Consideration of individual bioequivalence.

Authors:  S Anderson; W W Hauck
Journal:  J Pharmacokinet Biopharm       Date:  1990-06

3.  Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group.

Authors:  R Schall; R L Williams
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

4.  Measuring switchability and prescribability: when is average bioequivalence sufficient?

Authors:  W W Hauck; S Anderson
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

5.  On population and individual bioequivalence.

Authors:  R Schall; H G Luus
Journal:  Stat Med       Date:  1993-06-30       Impact factor: 2.373

  5 in total
  1 in total

1.  Evaluation of the bioequivalence of highly-variable drugs and drug products.

Authors:  L Tothfalusi; L Endrenyi; K K Midha; M J Rawson; J W Hubbard
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.